Analyst Price Targets — NMRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 1:20 pm | Brian Abrahams | RBC Capital | $5.00 | $1.60 | TheFly | Neumora Therapeutics price target lowered to $5 from $7 at RBC Capital |
| June 18, 2026 12:11 pm | — | Mizuho Securities | $4.00 | $1.50 | TheFly | Neumora Therapeutics price target lowered to $4 from $6 at Mizuho |
| January 12, 2026 10:20 am | Marc Goodman | Leerink Partners | $8.00 | $2.27 | TheFly | Neumora Therapeutics initiated with an Outperform at Leerink |
| January 5, 2026 2:51 pm | Graig Suvannavejh | Mizuho Securities | $6.00 | $1.72 | StreetInsider | Neumora Therapeutics (NMRA) PT Raised to $6 at Mizuho |
| December 1, 2025 10:35 am | — | RBC Capital | $7.00 | $2.24 | TheFly | Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital |
| October 28, 2025 11:50 am | — | Needham | $8.00 | $2.60 | TheFly | Neumora Therapeutics price target raised to $8 from $6 at Needham |
| March 7, 2025 9:48 am | — | Stifel Nicolaus | $2.00 | $1.49 | TheFly | Neumora Therapeutics downgraded to Hold from Buy at Stifel |
| January 2, 2025 4:06 pm | Brian Abrahams | RBC Capital | $4.00 | $1.97 | StreetInsider | RBC Capital Downgrades Neumora Therapeutics (NMRA) to Sector Perform |
| July 22, 2024 6:16 am | Ami Fadia | Needham | $23.00 | $11.28 | TheFly | Neumora Therapeutics initiated with a Buy at Needham |
| July 8, 2024 6:35 am | Graig Suvannavejh | Mizuho Securities | $20.00 | $10.25 | TheFly | Neumora Therapeutics initiated with an Outperform at Mizuho |
Latest News for NMRA
Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOAST
NEW YORK--(BUSINESS WIRE)--Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate workforce reduction of approximately 35%. Investors who lost money on NMRA are encouraged to submit their information now to discuss their legal…
Neumora Therapeutics reported data from its Phase 3 KOASTAL Program; the stock fell nearly 50%. NEW YORK, June 16, 2026 /PRNewswire/ -- Neumora Therapeutics (NASDAQ: NMRA) shareholders lost significant value today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate ~35% workforce reduction.
NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.
Neumora Therapeutics Inc. (NASDAQ:NMRA) on Monday said it is discontinuing development of its lead depression candidate, navacaprant, after two Phase 3 studies failed to achieve statistical significance on both primary and key secondary endpoints in patients with major depressive disorder (MDD).
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NMRA.
U.S. House Trading
No House trades found for NMRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.